BERNHARD R. WINKELMANN, M.D.; FRANK HERTRICH, M.D.
To the editor: We were very interested to read the report on almitrine by Bell and colleagues (1). There is, however, one specific detail that we could not determine, even after studying the article closely: were there any subgroups of patients who could be classified as almitrine responders and nonresponders?
We are currently evaluating several patients in a randomized, multicenter, hemodynamic trial of long-term almitrine therapy, and on the basis of our preliminary experience, we would like to propose another mechanism associated with this drug's intriguing capabilities in increasing arterial PO2 that has not been discussed in the literature so
WINKELMANN BR, HERTRICH F. Almitrine Bismesylate and Hypoxemia. Ann Intern Med. ;106:164. doi: 10.7326/0003-4819-106-1-164_1
Download citation file:
Published: Ann Intern Med. 1987;106(1):164.
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use